‘Conversations with Innovators:’ UNC hematologist on promising drug...
Kenneth Ataga, MD, director of the UNC Comprehensive Sickle Cell Program, was featured in a video by the American Society of Hematology in which he discussed the favorable results of a yearlong clinical trial studying crizanlizumab as a therapy to prevent and treat painful crisis events in patients with sickle cell disease.
